Definium Therapeutics Inc (DFTX) Stifel 2026 Virtual CNS Forum summary

Pipeline and clinical development

• Lead asset DT-120, a proprietary LSD tartrate, is in late-stage development for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with pivotal data from three studies expected later this year.

• Phase II data in GAD showed significant improvements in both anxiety and depression symptoms, supporting advancement to phase III and a breakthrough therapy designation for GAD.

• Phase III studies are designed to demonstrate efficacy in broad patient populations, including those with prior treatment failures, and focus on both regulatory and payer requirements.

• Durability of effect is a key focus, with primary endpoints at 6 weeks and extended observation to 12 weeks and beyond to assess long-term benefits.

• Regulatory strategy includes comprehensive data collection on both anxiety and depression domains to support robust labeling and market access.

Study design and execution

• Phase III GAD program includes two complementary studies: VOYAGE (100 mcg vs placebo) and PANORAMA (adds a 50 mcg decoy arm), both powered to detect a 5-point difference at high statistical power.

• Blinded sample size re-estimation in VOYAGE showed better patient retention and lower variance, increasing power to 99% for detecting efficacy.

• Multiple independent diagnostic and severity assessments are used at enrollment to ensure accurate patient selection and reduce risk from professional patients.

• Continuous site engagement and internal review processes are in place to maintain study integrity and alignment with intended populations.

Commercial and market considerations

• The eligible patient pool for DT-120 in MDD and GAD is estimated at 10–15 million, with even treating tens of thousands considered a significant impact.

• The treatment model is designed for predictable, single-day inpatient stays, which is operationally attractive for providers and patients.

• The company aims for broad market access and meaningful impact, not just niche adoption.